企业邮箱
Exchange Visits by High-Level Management Promoting the Comprehensive Initiation of MEBO New Business Plan of South Korea in Advance
2010年-11月-24日
来源：MEBO
MEBO Wound Ointment, the flagship product of MEBO has been stepping into the market of South Korea for more than ten years and has gained perfect public appraise by South Korean health care providers and citizens for its outstanding clinical efficacy. But due to a variety of reason, the velocity of sales expansion is still slow in spite of its rising tendency; all prescribed medications used in South Korea, as the developed country of East Asia, are the products approved by FDA. It is a long and tough process for the local medical field to accept the comprehensive clinical efficacy of MEBO products. Hence, the resistance of overall expansion of MEBO is much more we expected.
However, there are 97 hospitals (totally 200 large-scaled and national hospitals) now taking MEBO Ointment as the routine medicine after three years’ multiple efforts. With the steady proceed of marketing development in the recent years, MEBT/MEBO are now more and more being used in other departments, besides burn department. This year, several hospitals located in Seoul, Busan and Taegu has officially been applying MEBTMEBO in the treatment of integumentary disorders. Then the sales began to the stable increment.
In Nov, 2010, by the request of Hando trading firm (the agency of MEBO in South Korea) and Dongwha Pharmaceutical Co,. (the distributor of MEBO in South Korea), Ms. Sun Xia (President of MEBO International Marketing Department) and Mr. Liu Gang (Director of Marketing Department) paid an official visit to South Korea. Three parties retrospected the current status of MEBO in South Korea and conducted detailed discussion in terms of next year’s marketing development in South Korea. In the meeting, Ms. Sun introduced in details the up-to-date progress of MEBO science and the developing status of MEBO International Group in recent years to Mr. Chang_Soo Cho, the president of Dongwha Pharmaceutical Co,. Mr. Chang_Soo Cho expressed the wish that they would like to get long-term and deep cooperation with MEBO.
After careful discussion and repetitive exploration by three parties, the scientificity of MEBO products and corresponding incredible therapeutic effects were approved in consensus. The business plan of marketing expansion and leaping development had been established, in particular to the current marketing change and police adjustment. In the talks, Ms. Sun emphasized the significance of MEBO products in OTC market and required the MEBO agency and distributor to comprehensively activate the expanding plan of OTC market. Meanwhile, she stressed the importance of the multi-disciplinary application of MEBO products in the hospitals in order to ensure that there will have greater breakthrough for MEBO in the share of the market in the near future.
The agency and the distributor of MEBO in South Korea will visit the Beijing Headquarter of MEBO International Group in the next year to extensively put the business plan into practice. In the next year, the investment in every aspect of the South Korean market will be shot up, especially the agency and distributor of MEBO in South Korea had already confirmed that the invest capital of MEBO products will be increased. This talk has significant meaning with prolonged impacts for the overall development of MEBO market in South Korea that defined the superior position of MEBO products in South Korea and opened up a new model of marketing operation in the moderately developed country.
